Abstracts were recognised.
55. WILMS’
TUMOLIR
TIONAL
SOCIEN
Fa
the Trial
(WT)
J.de
(RT)
mndwnisotion
.
P.A.
Kmker,
Four studies were mdiothempy
conducted.
Fr~m this S~IQ in single
free survivol lhe record
versu* multiple
o prafare~~
pre-op.
85% respedively. with
unfavouroble receive
mndomised
in respectively
Stage II with
of stage. CT.
theropy with
* 70%.
paitive
ore mndomised
in respectively
in mointenonce
CT.
15
and AD.
and a.s.
of 84%.
were:
were 76%,
are rondcmised lymphnodes
50%
in correlation
and recurrence
with the whole
free survi-
series of SIOP
it was possible
to recognise
as a clinicopathological
entity with
this favo-
rable prognosis.
W%, of the
to 22%
58.
of the patients in the diagnceis SIOP
no. 6
Stage I potients concerning
are
CT.
post--.
VCR and odding
adriamycin is 6 months.
113 were suitabla
fa
trial.
CISPLATIN IN THETREATMENT OF RECURRENT WILMS' TLMOR. A.T' Meadows. J.Wilimas, J.Champion,J.Belasco, Children's Hospi-tal Cancer Research Center, Philadelphia.Pennsylvania,and Hospital, Memphis, Tennesthe St. Jude Children's Research see,
U.S.A.
Thirteen
ond stage 111 patients
in the last 2 groups
were registaed,
to drow conclusions.
factors
fibroade-
studying
included. 66%;
50%
In the 4th WT study AD and VCR.
CT
After
The 3rd WT study SIOP
gives no problem
intensified
Maintenonce
subtype
(VCR)
3 months and 6 months mointenance
lymphncdes
survival
Nephroblastomas,
Recumnce
(a.s.)
actuarial
val in comparison
watment.
161 patients
and a.s.
histology.
RT yes or no. Stage II with
1982 207 potients
and histological
with
had a stage I tumour capared
pre-ep.CT
negative
of 79%
This is o graat odvontage,
all patients
clinical
RT. A second
is just as goed as pre-cp.RT.
do nat need RT at 011. Pre-cp. of so-called
Q r.f.r.
r.f.s.
thempy
surgery.
pre-cpemtive
6 months to
vinvistine
irresfxxtive
Pm-ap.CT
pre-op.
immediate
is tos early
survival
those *een in fibro-
of the ovary this type is called: type of nephroblastoma.
p+9.
(CT)
RT to pre-op.
Fw the CT arm ond the RTarm
April
actuarial
of the likeness of the with
nomatous
courses of actinomycin
found fa
W(II
chemothew+y
is enough
compared
adenoma
M. Perry,
cowses AD wen found.
could be found with
6 months CT
potients
by pat-op.
Because
structures
1971-1982.
H.J.
ene concerning
study WOI non-rondomiseded. It concemed
NO differente
with
(SIOP)
histological
Villejuif/Paris.
The fint
to multiple
THE INTERNA-
Tournode,
surgery followed
being ?? 50%,
(r.f.s.)
months of maintemnce
no.5
M.F.
Amsterdam,
to direct
FROM
ONCOLOGY
Vo&e,
was doneinsingle
NO diffennce
STUDIES
OF PAEDIATRIC
Camnittee:
J. Lemerle,
D (AD)
TRIALS AND
It
The study goes on. The conclusionfrcm
al1 the studies is: centmlized treotment of this rare diseose in children is necessary. Re-CQ. CT should be given to all patients with (t WT.
56.
NEPHROBLASTOMASTAGE IV. For the Trial Committee:J.de Kralrer, p.Bey, D.Bf&er, M.Carli, C.Nihoul-Fékété,P.A.Voûte, J.Lemerle.Amsterdam,Villejuif/Paris. Under supervisionof the organisingcormnittee of the "ephroblastomatrials and studies of SIOP, s multi-center pilot study was designed. In this study the definitionof Wilms' tumour stage IV patients wil1 be .restrictedto those with haematogenouslung metastasesat presentation.Rationals for the study were: & The stil1 unfavourableprognosis of patients with stage IV disease.0 The need for a more uniform treatmentprotocol,2 To study the possibilityof cutting on lung irradiationin some of these patients. To reach this, it ~8s decided to initiallyintensifythe pre-operativechemotherapy (CT). This vil1 consist of Actinowcin D (AD) 15 unr/ hg/i.v. day 1, 2, 3 - 15, 16, 17 - 29, 30,.31. Vincristin _ (VCR) 1.5 ma/m'/i.v. once B week for 6 weeks. and Adriamvcin (AZ)R)25 mg/m2 dsy 8, 22 > 36. After nephrectómy,metaststectomy wil1 be considered.Pcstoperativetreatmentuil1 depend on the fact if metastaseswe stil1 demonstrableand the local stage of the tumour. Lung irradiationis necessary I" case of incompleteresected or inoperablemetastases. In case of B local stage 11 tumour vith positive lymphnodesoi stage II!, radiotherapyis given to the abdomen according to the protocol SIOP VI. PostoperativeCT wil1 consist of AD 15 ugr/ hg for three consecutivedays and VCR 1.5 mg/m2 once a week for at least 4 weeks. Maintenancetherapy wil1 be the s~me for al1 the patients.To start with VCR 1.5 mg/m'/i.v.and ADR 50 mgjm'li.v. four times with a three week interval followed by 5 courses AD 15 ugr/kg/i.v.5 days and VCR 1.5 mg/m' i.v. day 1 and day 5 every 3 weeks. Besides actuarial and disease free survival,cardiotoxicityand ether treatment related sequelaevil1 be of special concern.
patients received cisplatin for recurrent or unrespo"siveWilme' tumor and 3 of the 12 who were evaluable The inevaluablepatient had transtentand partial responses. was a 6 year old female with recurrent pulmonary metastases who died hours after the infusion. Al1 had received Víncristine, Actinomycin D and Adriamyci" prior to the administration of cisplatinand most had received pulmonary and abdomi"al irradiation. Two patients demonstratedpartial clearing of pulmonary metastases which lasted for 2 and 3 months, while ene patient had P decrease in the size of bis abdominal rec"rre"ce. This lasted 3 months but grew back jusc prior to a scheduled laparotomy for removal of the residual tumor. The dose of cisplatinused was fairly uniform: 90 mg/m' or 1 mglkg. The characteristicsof these patients differed somewhat from the usual populatíon of Wilms' tumor patients; 8 were 111 or male and 4 were female. The majority (9) were Stages
It is noteworthy that while the media” age IV at diagnosis. of the patients was 4 years, the 3 patients vith early stage disease in fhis groq were 7, 9 and 14 years of age. In addition, of the 3 patíents vith unfavorable histologie types, tvo were the only black patients and ene was a 13 month old white male. We conclude that cisplstín may have some efficacy in the therapy of Wilms’ of its use earlier in the tumor and studies pro~ression of disesse should be coneidered. Supported in part by a grant from the National Institutesof
Health (CA 14489).
59. IS
TOTAL
NEPHRECTOMY
TREATMENT
OF
J.Valenca
M.Sousinha. -
Qus!roz.
Clinlca
tituto
Português
Llsboa
-
It
has
to
lignant
AOVISABLE
.
! de
THE
MertinS.
Sousa,M.A.Picanco.
Oncolöglca de
IN
A.Gentll
Oncologia
32.
IV
[Pediatria),
de
Francisco
InsGentil.
Portugal.
been
world'
ALWAYS
NEPHROELASTOMA
standard
perform
policy
total
tumors
of
almost
al1
over
mp~rournterectomy
the
ktdney,
the
for
mainly
for
md-
nephro-
blastoma. Oue
to
advances
results
in
obtained
technically
chematherapy
we
felt
possible
to preserve
the
[
and
it
the
impraved
justified,
section
on
non-involved
whenever
normal
pratian
1
tissues
of
the
kl-
dney. Of
d
of
total
performed
[
80
nephrectamies and
3,.
J.F.M.Delemarre, S.I.O.P.
TYPE OF NEPHROBtASTOMA.
B.Sandstedt,
Nephroblastoma
Emma Kinderziekenhuis,
M.F.Tournade,
Trial and Study, 1018 HJ
secretary:
Amsterdam,
there to
The
tha
After
revision
of the microscopical
sections
of
from the files of the SIOP Nephroblas-
toma Study and Trial
25 cases of a special
wàs
10
1.
These
in
ene
10 case
local
fellow-up
1
wlth
in
in cass
"ear
biiateral
metastases.
Al1
4y, 8
This
latter
[
tumor ethers
12
díed? are
kidneyl. 3y.
2y(r31.
harseshoe
kidney
patient
has
hemi-
tumor
horseshoe
6y. of
recurrence.
had
bilateral a
By,
the
heminephrectomy
+or
recurrence
respectlvely Only
had
oatients
1
and
died so
wbs
far
lost
onlv
from
the
pblma-
alive
and
well. We fel1 that there is a ces8 to be conservative
Netherlands.
889 patients
is
lw.
patient nary
for
up
lY(X21.
for the
[
another
Fellow
THE FIBROADENOMATOUS
patients
10%
subtype
in
surgical polar
recurrence of
tumor
trsatmsnt
tumors. if
with surgery
ressection.
of na
Nephroblastoma, increased
respects
risk the
basic
namelly of
local
principles
In